Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Royalty Pharma plc RPRX

Healthcare Biotechnology
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including... see more

Recent & Breaking News (NDAQ:RPRX)

Royalty Pharma to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

GlobeNewswire June 8, 2022

Royalty Pharma to Present at the UBS Global Healthcare Conference 2022

GlobeNewswire May 23, 2022

Royalty Pharma Investor Day Highlights Stronger Growth Outlook and the Power of Its Unique Business Model to Drive Value for All Stakeholders

GlobeNewswire May 17, 2022

Royalty Pharma Reports First Quarter 2022 Results

GlobeNewswire May 5, 2022

Royalty Pharma Declares Second Quarter 2022 Dividend

GlobeNewswire April 18, 2022

Royalty Pharma to Announce First Quarter 2022 Financial Results on May 5, 2022

GlobeNewswire April 13, 2022

Royalty Pharma Announces Charitable Alliance with The Leukemia & Lymphoma Society (LLS) To Advance Initiatives that Address Healthcare Disparities in Blood Cancer Care and Treatment

PR Newswire March 29, 2022

Royalty Pharma to Present at Cowen's 42nd Annual Health Care Conference

GlobeNewswire March 3, 2022

Royalty Pharma Announces Inaugural Investor Day

GlobeNewswire February 16, 2022

Royalty Pharma Reports Q4 and Full Year 2021 Results

GlobeNewswire February 15, 2022

Royalty Pharma to Announce Fourth-Quarter and Full-Year 2021 Financial Results on February 15, 2022

GlobeNewswire January 20, 2022

Royalty Pharma Highlights Accomplishments and Provides Business Update at 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 10, 2022

Royalty Pharma and Cytokinetics Announce Funding Agreements Totaling up to $450 Million

GlobeNewswire January 7, 2022

Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million

GlobeNewswire January 7, 2022

Royalty Pharma Announces 12% Dividend Increase

GlobeNewswire January 6, 2022

Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 10

GlobeNewswire January 5, 2022

Royalty Pharma to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference

GlobeNewswire November 29, 2021

Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and ORLADEYO from BioCryst Pharmaceuticals

GlobeNewswire November 22, 2021

Royalty Pharma Reports Third Quarter 2021 Results

GlobeNewswire November 10, 2021

Royalty Pharma to Announce Third-Quarter 2021 Financial Results on November 10, 2021

GlobeNewswire October 18, 2021